FCGRT and myasthenia gravis: The more recent approval of the mAb rozanolixizumab for generalized, acetylcholine receptor– and muscle-specific tyrosine kinase antibody–positive myasthenia gravis has expanded the range of drugs acting via FcRn antagonism (46, 47).